Quanterix Corp Chief Legal Officer Daniel Char has reported initial equity holdings. The filing shows grants received on January 15, 2026 of 33,962 restricted stock units tied to common stock and 113,171 stock options to buy common shares at an exercise price of $7.95 per share. Both awards vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, creating a multi-year incentive structure aligned with continued service.
Quanterix Corp’s Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. On March 15, 2026, multiple restricted stock unit awards converted into common stock, with derivative exercises totaling 1,558 shares according to the filing’s transaction summary.
To cover related tax obligations, 549 common shares were withheld at a price of $4.72 per share under code F transactions, which are tax-withholding dispositions rather than market sales. Following these transactions, Miller directly holds 31,271 shares of Quanterix common stock.
Quanterix Corp Chief Operating Officer Michael Francis Miller filed an initial ownership report showing his equity-based holdings in the company. As of February 23, 2026, he holds 74,905 Performance Stock Units granted on February 15, 2026, which vest in four equal annual installments after meeting performance conditions under the 2026 Employee Equity Guidelines.
He also holds multiple Restricted Stock Unit awards, including 74,905 RSUs granted on February 15, 2026 that vest 25% per year for four years, plus earlier RSU grants from 2022–2025 with monthly vesting schedules after the first anniversary. In addition, he has several option grants to buy Common Stock at exercise prices between $8.4300 and $54.0400 per share, with expirations between July 28, 2031 and February 4, 2035, and directly owns 30,262 shares of Common Stock.
Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On March 15, 2026, she exercised RSUs covering 1,833 common shares in total through derivative exercises.
To satisfy tax obligations, 645 common shares were withheld and disposed of at $4.72 per share, with the remaining shares added to her direct holdings. Following these transactions, she directly owned 27,428 shares of Quanterix common stock. The RSUs stem from prior grants of 12,624 units on August 21, 2023, 24,675 units on February 2, 2024, and 50,712 units on February 4, 2025, each vesting over time with an initial 25% cliff and subsequent monthly installments.
Quanterix Corporation outlines how it is building a biomarker and spatial biology platform spanning research to diagnostics. The company now has over 2,500 instruments installed and more than 6,200 scientific publications citing its Simoa and Spatial Biology technologies in neurology, oncology, immunology, and inflammation.
In 2025 Quanterix acquired Akoya Biosciences, adding high-plex tissue imaging, and Emission, Inc., securing bead manufacturing and a mid-plex platform. It is pushing into Alzheimer’s diagnostics with its LucentAD Complete multi-marker blood test, which received a $897 Medicare reimbursement rate, and a multi-analyte blood test that has FDA Breakthrough Device Designation and a submitted 510(k) for detecting amyloid pathology.
The report also highlights governance and leadership changes, including new directors, a new CEO, and a cooperation agreement with Kent Lake Partners, as Quanterix positions its technology and CLIA-certified laboratory services for broader diagnostic use.
Quanterix reported fourth quarter and full-year 2025 results and issued its 2026 outlook. Q4 2025 revenue was $43.9 million, up from $35.2 million, while full-year revenue was $138.9 million versus $137.4 million in 2024. GAAP gross margin fell to 46.8% for 2025 from 60.5%, and the company recorded a net loss of $107.2 million, wider than $38.5 million a year earlier. Adjusted EBITDA loss was $44.9 million.
Quanterix ended 2025 with $121.6 million in cash, cash equivalents, marketable securities and restricted cash and has implemented $74 million of an $85 million cost-synergy target tied to the Akoya acquisition. The company submitted a 510(k) to the FDA for its multi-analyte Alzheimer’s blood test and CMS set a $897 reimbursement rate for the LucentAD Complete test. For 2026, Quanterix guides to revenue of $169–$174 million, GAAP gross margin of 45–49%, adjusted gross margin of 49–53%, and expects to reach cash flow breakeven in the second half of 2026 and exit the year with about $100 million in cash and no debt.
Quanterix Corp’s chief financial officer, Vandana Sriram, reported equity award and related tax transactions. The CFO received grants of 74,905 performance stock units and 74,905 restricted stock units at a stated price of $0 per unit. Footnotes explain that PSUs vest based on performance conditions and then in four equal annual installments starting on the first anniversary of the grant date, while the new RSU award also vests in four equal annual installments.
The filing also shows exercises of previously granted restricted stock units into common stock, along with share dispositions to cover tax obligations. Specifically, 514 and 263 RSUs were converted into common stock, and 179 and 92 common shares were withheld at $5.74 per share to satisfy tax liabilities. After these transactions, the CFO directly held 26,240 shares of Quanterix common stock.
Quanterix Corp. received an amended Schedule 13G/A showing that a group of affiliated Ameriprise entities collectively report beneficial ownership of 4,996,073 shares of Quanterix common stock, representing 10.7% of the class as of 12/31/2025.
The filing lists Ameriprise Financial, Inc. and multiple UK- and Luxembourg-based subsidiaries with shared voting and dispositive power over these shares. The Ameriprise entities state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Quanterix.
Quanterix Corporation’s Chief Financial Officer, Sriram Vandana, reported a routine tax-related share withholding. On February 4, 2026, 4,395 shares of common stock were withheld by Quanterix to cover tax obligations from the vesting of 12,678 restricted stock units (RSUs).
After this transaction, the CFO beneficially owned 81,618 shares of Quanterix common stock, which includes 55,884 RSUs. This filing reflects a non-open-market transaction coded "F," indicating shares retained for taxes rather than a discretionary sale into the market.
Quanterix CorpEverett CunninghamJanuary 19, 2026813,750 performance-based restricted stock units (RSUs)1,070,000 time-based RSUs
The performance-based RSUs vest only if the volume-weighted average price of Quanterix stock meets specified thresholds within a four-year period, as outlined in his January 8, 2026 employment agreement. The time-based RSUs vest in four equal annual installments on January 19, 2027, 2028, 2029, and 20301,883,750 derivative securities$0